Education
About Us
Working with TipRanks
Follow Us
RenovoRx (RNXT)
NASDAQ:RNXT
Earnings Data
Report Date
Nov 17, 2025After Close (Confirmed)
Period Ending
2025 (Q3)Consensus EPS Forecast
-0.08Last Year’s EPS
-0.1Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with significant achievements in commercial sales and clinical trial progress, despite challenges in sales infrastructure and ongoing R&D expenses.Company Guidance
Commercialization Success
RenovoRx achieved over $400,000 in sales in Q2 2025 without a dedicated sales and marketing team, highlighting strong market demand for the RenovoCath device.
Positive Interim Analysis for TIGR PACT Trial
The independent Data Monitoring Committee (DMC) recommended the continuation of the Phase III TIGR PACT trial, indicating confidence in a potential positive outcome.
Strong Financial Position
RenovoRx ended the quarter with $12.3 million in cash and cash equivalents, sufficient to fund ongoing commercial and clinical activities.
Panther Registry Study Launch
RenovoRx launched the Panther study to evaluate the real-world safety and effectiveness of RenovoCath in solid tumors, marking a significant step in understanding the device's long-term potential.
Market Expansion Potential
RenovoRx estimates a $400 million peak annual U.S. sales opportunity for RenovoCath as a standalone device, with potential expansion into a several billion dollar market for additional cancer applications.
RNXT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
RNXT Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Aug 14, 2025 | $1.24 | $0.96 | -22.58% |
May 15, 2025 | $1.11 | $1.18 | +6.31% |
Apr 01, 2025 | $0.99 | $0.96 | -3.03% |
Nov 14, 2024 | $1.09 | $1.09 | 0.00% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does RenovoRx (RNXT) report earnings?
RenovoRx (RNXT) is schdueled to report earning on Nov 17, 2025, After Close (Confirmed).
What is RenovoRx (RNXT) earnings time?
RenovoRx (RNXT) earnings time is at Nov 17, 2025, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is RNXT EPS forecast?
RNXT EPS forecast for the fiscal quarter 2025 (Q3) is -0.08.